Newspaper advertisements of unaudited financial results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem Limited has submitted copies of newspaper advertisements (Business Standard English edition and Loksatta Gujarati edition, both dated November 14, 2025) publishing its unaudited financial results for Q2 and H1 FY26, as required under SEBI LODR Regulation 47(3). For the quarter ended September 30, 2025, total income from operations stood at Rs. 634.10 lakhs, with a marginal net profit of Rs. 1.23 lakhs and EPS of Rs. 0.03, a sharp decline from Q1 FY26 which posted Rs. 802.40 lakhs in revenue and Rs. 50.97 lakhs profit. For H1 FY26, total income was Rs. 1,436.50 lakhs (vs Rs. 1,427.47 lakhs in H1 FY25), but the company swung to a net profit of Rs. 52.19 lakhs compared to a loss of Rs. 2.88 lakhs in the same period last year. Full-year FY25 had ended in a loss of Rs. 140.25 lakhs, highlighting the recent turnaround.
The H1 turnaround from loss to profit is positive, but the steep sequential drop in Q2 profit and revenue suggests weak momentum in the second quarter, which may concern short-term investors despite the year-on-year improvement.